How do I install the Ppgl Lifelong Follow Up Duration skill?

Run npx skillmds@latest add dromlakhani/ppgl-lifelong-follow-up-duration in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Ppgl Lifelong Follow Up Duration safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Ppgl Lifelong Follow Up Duration?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Ppgl Lifelong Follow Up Duration free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Ppgl Lifelong Follow Up Duration?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Ppgl Lifelong Follow Up Duration by dromlakhani

Name: Ppgl Lifelong Follow Up Duration
Rating: 4.2 (5 reviews)
Author: dromlakhani

Ppgl Lifelong Follow Up Duration

Determines appropriate postoperative follow-up duration for PPGL based on hereditary status, catecholamine phenotype, tumor size, and location to guide surveillance intensity. Recommends lifelong follow-up for hereditary PPGL and at least 10 years for sporadic PPGL with noradrenaline dominance, tumor ≥5 cm, or extra‑adrenal/PGL location; triggers include 'Post-op PPGL patient requiring follow-up plan,' 'Assessing need for extended surveillance in PPGL survivor,' 'Determining follow-up duration for cured PPGL patient.'

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Lifelong PPGL Follow-Up Duration Determination Based on Risk Factors

STEP 1 — Gather Information

Collect hereditary status (germline genetic testing), catecholamine dominance (noradrenaline vs adrenaline), tumor size in centimeters, tumor location (adrenal, extra‑adrenal, head‑and‑neck PGL), patient age, and presence of preoperative catecholamine overproduction.
→ Proceed to assess hereditary status.

STEP 2 — Rule In / Rule Out

Is there a confirmed germline pathogenic variant indicating hereditary PPGL?

Yes → Recommend lifelong follow‑up (proceed to Step 4 for hereditary pathway).
No → Proceed to risk stratification for sporadic PPGL.

STEP 3 — Classify or Stratify

For sporadic PPGL, evaluate high‑risk features: noradrenaline dominance, primary tumor diameter ≥5 cm, or extra‑adrenal/abdominal PGL location (outside head‑and‑neck).

If any high‑risk feature present → Classify as high‑risk sporadic PPGL.
If none present → Classify as low‑risk sporadic PPGL.
→ Proceed to decision step.

STEP 4 — Decide

Hereditary PPGL: Implement lifelong clinical follow‑up with biochemical testing every 6–12 months and imaging (MRI/CT) every 1–2 years indefinitely.
High‑risk sporadic PPGL: Schedule follow‑up for a minimum of 10 years with biochemical testing every 6 months and imaging every 1–2 years; consider extension beyond 10 years based on persistent risk factors.
Low‑risk sporadic PPGL: Provide minimum 10‑year follow‑up with biochemical testing annually and imaging every 2–3 years.
→ Implement the individualized follow‑up plan.

Clinical Guardrails / Mimics / Pitfalls

Do not discontinue surveillance before 10 years even if biomarkers normalize; avoid relying solely on serum metanephrines for risk assessment; omit imaging only in low‑risk cases after thorough discussion; young age (<40 years) warrants consideration of extended surveillance regardless of other factors; extra‑adrenal PGL (abdominal) confers higher metastatic risk than head‑and‑neck PGL; head‑and‑neck PGL may still need long‑term follow‑up if SDHB variant is present; ensure patients understand the lifelong commitment for hereditary PPGL.

Concrete Clinical Example

A 48‑year‑old man underwent resection of a 6 cm abdominal paraganglioma with noradrenaline dominance; germline testing was negative. He has no head‑and‑neck involvement. Classified as high‑risk sporadic PPGL due to tumor ≥5 cm and noradrenaline dominance. Follow‑up plan: plasma‑free metanephrines and urinary fractionated metanephrines every 6 months, contrast‑enhanced MRI of abdomen/pelvis annually for the first 5 years then every 1–2 years, with lifelong consideration after 10 years given persistent risk factors.

Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165

---name: ppgl-lifelong-follow-up-durationdescription: Determines appropriate postoperative follow-up duration for PPGL based on hereditary status, catecholamine phenotype, tumor size, and location to guide surveillance intensity. Recommends lifelong follow-up for hereditary PPGL and at least 10 years for sporadic PPGL with noradrenaline dominance, tumor ≥5 cm, or extra‑adrenal/PGL location; triggers include 'Post-op PPGL patient requiring follow-up plan,' 'Assessing need for extended surveillance in PPGL survivor,' 'Determining follow-up duration for cured PPGL patient.'---# Lifelong PPGL Follow-Up Duration Determination Based on Risk Factors## STEP 1 — Gather InformationCollect hereditary status (germline genetic testing), catecholamine dominance (noradrenaline vs adrenaline), tumor size in centimeters, tumor location (adrenal, extra‑adrenal, head‑and‑neck PGL), patient age, and presence of preoperative catecholamine overproduction. → Proceed to assess hereditary status.## STEP 2 — Rule In / Rule OutIs there a confirmed germline pathogenic variant indicating hereditary PPGL? - Yes → Recommend lifelong follow‑up (proceed to Step 4 for hereditary pathway). - No → Proceed to risk stratification for sporadic PPGL.## STEP 3 — Classify or StratifyFor sporadic PPGL, evaluate high‑risk features: noradrenaline dominance, primary tumor diameter ≥5 cm, or extra‑adrenal/abdominal PGL location (outside head‑and‑neck). - If any high‑risk feature present → Classify as high‑risk sporadic PPGL. - If none present → Classify as low‑risk sporadic PPGL. → Proceed to decision step.## STEP 4 — Decide- Hereditary PPGL: Implement lifelong clinical follow‑up with biochemical testing every 6–12 months and imaging (MRI/CT) every 1–2 years indefinitely. - High‑risk sporadic PPGL: Schedule follow‑up for a minimum of 10 years with biochemical testing every 6 months and imaging every 1–2 years; consider extension beyond 10 years based on persistent risk factors. - Low‑risk sporadic PPGL: Provide minimum 10‑year follow‑up with biochemical testing annually and imaging every 2–3 years. → Implement the individualized follow‑up plan.## Clinical Guardrails / Mimics / PitfallsDo not discontinue surveillance before 10 years even if biomarkers normalize; avoid relying solely on serum metanephrines for risk assessment; omit imaging only in low‑risk cases after thorough discussion; young age (<40 years) warrants consideration of extended surveillance regardless of other factors; extra‑adrenal PGL (abdominal) confers higher metastatic risk than head‑and‑neck PGL; head‑and‑neck PGL may still need long‑term follow‑up if SDHB variant is present; ensure patients understand the lifelong commitment for hereditary PPGL.## Concrete Clinical ExampleA 48‑year‑old man underwent resection of a 6 cm abdominal paraganglioma with noradrenaline dominance; germline testing was negative. He has no head‑and‑neck involvement. Classified as high‑risk sporadic PPGL due to tumor ≥5 cm and noradrenaline dominance. Follow‑up plan: plasma‑free metanephrines and urinary fractionated metanephrines every 6 months, contrast‑enhanced MRI of abdomen/pelvis annually for the first 5 years then every 1–2 years, with lifelong consideration after 10 years given persistent risk factors.**Source:** Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165

Frequently asked questions